Skip to main content

Table 1 Characteristics of the studied gene polymorphisms

From: Polymorphisms in Phase I and Phase II genes and breast cancer risk and relations to persistent organic pollutant exposure: a case–control study in Inuit women

Gene

Position

Reference SNP

Location/amino acid change

Genotyping method

Main function

Activity

Low

High

CYP1A1

15q24.1

rs1048943

A> C

C_25624888_50#

Carcinogen activation

Ile (wt)

Val (var)

Ile462Val

2-hydroxylation of E2

CYP1B1

2p22.2

rs1056836

C> G Leu432val

C_3099976_30#

Carcinogen activation

Leu (wt)

Vala (var)

4-hydroxylation of E2

COMT

22q11.21

rs4680

G> A

C_25746809_50#

Estradiol catabolism

Met (mut)

Val (var)

Val158Met

CYP17A1

10q24.3

rs743572

5′UTR

C_2852784_30#

Steroid 17α-hydroxylase

 

A2b

−34 T> C (A1> A2)

CYP19A1

15q21.1

rs10046

3′UTR

C_8234731_30#

Aromatase activity (androgen to estrogen)

 

Tc (var)

C> T

CYP19A1

15q21.1

-

(TTTA)n repeats

PCR-based

Aromatase activity

-

-

BRCA1

17q21

rs80357164

Cys39Gly

PCR-based

DNA damage repair

-

-

  1. wt: wild-type; var: variant.
  2. #TaqMan Drug Metabolism Genotyping Assay.
  3. a432Val variant has the higher 17β-estradiol hydroxylation activity, but lower carcinogenic activity [14].
  4. bA2 is postulated to correlate with higher serum levels of various sex steroids [22, 24, 25].
  5. cVariant alleles T has been associated with higher levels of postmenopausal circulating E2 [27].